Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
July 21, 2020 8:51 AM EDT
BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors.
BioNTech announced the commencement of a firm commitment underwritten offering (the Underwritten Offering) of 5,000,000 American Depositary Shares (ADSs), each representing one of its ordinary shares. In connection with the Underwritten Offering, an existing shareholder intends to grant the...
More
July 21, 2020 8:42 AM EDT
Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.
Risinger await results from BNT162b2(full spike)... More
July 20, 2020 10:57 AM EDT
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive progress on its COVID vaccine.
The analyst commented, "We are encouraged by new data from Pfizer and partner BioNTech on the progress they are... More
